Company / Cash & Equivalents
Bionano Genomics, Inc. Cash & Equivalents History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$3.0M
FY2025
5-year range
$3.0M / $24.6M
FY2021-FY2025
Trend
-67.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents has fluctuated over the past 8 years, ranging from $3M in FY2025 to $38M in FY2020.
Based on SEC 10-K filings.
$3M in FY2025 with a 5-year CAGR of -40.0%.
Declined from $18M to $3M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -16.3%
- 5-Year CAGR
- -40.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -40.0%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 67.4% year-over-year.
- Peak cash & equivalents was recorded in FY2020.
Company context
Key Data Points
- Altman Z-Score -8.45 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.0M | -67.4% |
| FY2024 | $9.2M | -48.9% |
| FY2023 | $17.9M | +252.5% |
| FY2022 | $5.1M | -79.3% |
| FY2021 | $24.6M | -36.1% |
| FY2020 | $38.4M | +122.1% |
| FY2019 | $17.3M | +4.8% |
| FY2018 | $16.5M | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 22, 2026